Department of Hematology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, Beijing 100730, China.
Chin Med J (Engl). 2010 Feb 5;123(3):305-10.
Hemophilia A (HA) is an X-linked inherited bleeding disorder caused by decreased activity of factor VIII (FVIII) due to heterogenous mutations in the FVIII coding gene (F8). The type of mutation plays an important role in the FVIII inhibitor formation. To date, several studies on the spectra of F8 defects have been performed in Western populations, but similar studies in Asian races are scarce. Here, we reported the distribution of the F8 gene mutations in 18 unrelated Chinese patients with HA.
Intron 22 and intron 1 inversions in the F8 gene were screened in 158 unrelated patients with HA using a long-distance PCR and multiplex PCR method. Direct sequencing of the coding region of the F8 gene was used to identify the mutations responsible for HA in 18 unrelated Chinese HA patients who were negative for intron 22 and intron 1 inversions; sequences were compared with the HAMSTeRS database. A clotting method was used to assay the FVIII activity level and the Bethesda assay was used to detect the FVIII inhibitor.
A total of 18 different HA F8 mutations were identified, seven of which were described for the first time. These novel mutations included five small deletions, one point mutation and one small insertion. One novel mutation (4382-3 AC deletion) was associated with inhibitor development.
These data extend our insight into the mechanisms by which novel amino acid mutations may lead to HA and how the HA patient genotypes influence the risk of FVIII inhibitor.
血友病 A(HA)是一种 X 连锁遗传性出血性疾病,由于 FVIII 编码基因(F8)中的杂合突变导致因子 VIII(FVIII)活性降低而引起。突变类型在 FVIII 抑制剂形成中起着重要作用。迄今为止,已经在西方人群中进行了几项关于 F8 缺陷谱的研究,但在亚洲人群中类似的研究很少。在这里,我们报告了 18 例无血缘关系的中国 HA 患者中 F8 基因突变的分布。
采用长距离 PCR 和多重 PCR 方法筛选 158 例无血缘关系的 HA 患者的 F8 基因内含子 22 和内含子 1 倒位。对 18 例无血缘关系的中国 HA 患者进行 F8 基因编码区直接测序,这些患者的内含子 22 和内含子 1 倒位均为阴性,负责 HA 的突变;序列与 HAMSTeRS 数据库进行比较。采用凝血法检测 FVIII 活性水平,采用 Bethesda 法检测 FVIII 抑制剂。
共发现 18 种不同的 HA F8 基因突变,其中 7 种为首次报道。这些新的突变包括 5 种小缺失、1 种点突变和 1 种小插入。一种新的突变(4382-3AC 缺失)与抑制剂的发展有关。
这些数据扩展了我们对新型氨基酸突变如何导致 HA 以及 HA 患者基因型如何影响 FVIII 抑制剂风险的认识。